La cadena de opciones muestra datos clave de las opciones de acciones de Quince Therapeutics a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Quince Therapeutics..

Quince Therapeutics (NASDAQ:QNCX) Bolsa, Cadena de Opciones

Quince Therapeutics

Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing innovative precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics.

Quince Therapeutics Inc

Throughout the last three months, 5 analysts have evaluated VICI Props (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VICI#NYSE">VICI</a>), offering a diverse set of opinions from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $35.4, a high estimate of $37.00, and a low estimate of $33.00. Marking an increase of 2.91%, the current average surpasses the previous average price target of $34.40. 
<img src="https://www.benzinga.com/files/images/story/2024/1731600017_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
A comprehensive examination of how financial experts perceive VICI Props is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Haendel St. Juste</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$33.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Mitch Germain</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$35.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Conor Siversky</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$36.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Steve Sakwa</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$37.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Steve Sakwa</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$36.00</td>
<td>$35.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to VICI Props. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of VICI Props compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
To gain a panoramic view of VICI Props's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/VICI/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on VICI Props analyst ratings.</a>
<h2>Get to Know VICI Props Better</h2>
VICI Properties Inc is a real estate investment trust based in the United States. It engaged in the business of owning and acquiring gaming, hospitality, and entertainment destinations, subject to long-term triple net leases. The company's operating segments are real property business and golf course business. The Real property business segment consists of leased real property whereas the Golf course business segment consists of several golf courses. Its golf courses include the Cascata Golf Course, the Rio Secco Golf Course, the Grand Bear Golf Course, and the Chariot Run Golf Course.
<h3>A Deep Dive into VICI Props's Financials</h3>
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
Revenue Growth: Over the 3 months period, VICI Props showcased positive performance, achieving a revenue growth rate of 6.67% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Real Estate sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 75.97%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): VICI Props's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.83% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): VICI Props's ROA stands out, surpassing industry averages. With an impressive ROA of 1.64%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: VICI Props's debt-to-equity ratio is below the industry average at 0.68, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: Simplified</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

VICI

What 5 Analyst Ratings Have To Say About VICI Props

In the latest quarter, 5 analysts provided ratings for EPR Props (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPR#NYSE">EPR</a>), showcasing a mix of bullish and bearish perspectives.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $49.0, a high estimate of $54.00, and a low estimate of $45.00. This current average has increased by 3.7% from the previous average price target of $47.25. 
<img src="https://www.benzinga.com/files/images/story/2024/1731600009_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
A comprehensive examination of how financial experts perceive EPR Props is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Goldsmith</td>
<td>UBS</td>
<td>Announces</td>
<td>Neutral</td>
<td>$48.00</td>
<td>-</td>
</tr>
<tr>
<td>Conor Siversky</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Underweight</td>
<td>$47.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Anthony Paolone</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$51.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>James Feldman</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Underweight</td>
<td>$45.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>RJ Milligan</td>
<td>Raymond James</td>
<td>Maintains</td>
<td>Strong Buy</td>
<td>$54.00</td>
<td>$54.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to EPR Props. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of EPR Props compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of EPR Props's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of EPR Props's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/EPR/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on EPR Props analyst ratings.</a>
<h2>Get to Know EPR Props Better</h2>
EPR Properties is a real estate investment trust that leases experiential properties in the United States and Canada. The company invests in two property segments: Experiential, including theaters, family entertainment centers, ski resorts, and other attractions; and Education, including early childhood education centers and private school properties. New investments are determined based on value and opportunity of the respective industry, location quality, and credit quality of tenants. The majority of revenue comes from the Experiential sector.
<h3>Unraveling the Financial Story of EPR Props</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Decline in Revenue: Over the 3 months period, EPR Props faced challenges, resulting in a decline of approximately -6.79% in revenue growth as of 30 September, 2024. This signifies a reduction in the company's top-line earnings. When compared to others in the Real Estate sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 24.91%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): EPR Props's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.68% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): EPR Props's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 0.72%, the company may face hurdles in achieving optimal financial performance.
Debt Management: EPR Props's debt-to-equity ratio is below the industry average at 1.28, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Analyst Verdict: EPR Props In The Eyes Of 5 Experts

Canaccord Genuity analyst Sumant Kulkarni maintains Clene (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLNN#NASDAQ">CLNN</a>) with a Buy and lowers the price target from $86 to $83.

News

Price Target

CLNN

Canaccord Genuity Maintains Buy on Clene, Lowers Price Target to $83

BMO Capital analyst John McNulty maintains Air Products &amp; Chemicals (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APD#NYSE">APD</a>) with a Outperform and raises the price target from $323 to $350.

BMO Capital Maintains Outperform on Air Products & Chemicals, Raises Price Target to $350

Rumors

Trading Ideas

TCMD

Watching Tactile Systems Technology; Traders Circulate Stock Picked By Zacks Homerun Newsletter

GETY

Getty Images Partners With TikTok To Provide Advertisers Direct Access To Premium Creative Content, Enabling Seamless Ad Creation Through TikTok's Symphony Creative Studio

Roth MKM analyst Joe Reagor reiterates Avino Silver &amp; Gold Mines (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ASM#AMEX">ASM</a>) with a Buy and lowers the price target from $1.9 to $1.8.

Reiteration

Roth MKM Reiterates Buy on Avino Silver & Gold Mines, Lowers Price Target to $1.8

The European Union's Markets in Crypto-Assets (MiCA) regulation, set for full implementation by December, is expected to provide a structured framework that could reshape <a href="https://www.benzinga.com/topic/mica">the European crypto landscape</a>. 
Adam Guren, founder and chief investment officer of Hunting Hill Global Capital, sees MiCA as a promising development that could attract more institutional involvement in digital assets by establishing clearer regulatory standards.
<h3 class="wp-block-heading">Clarity in Compliance and Investor Confidence</h3>
Guren described MiCA's rollout as a "positive evolution" for firms in the crypto space, noting that the regulation is expected to create a more defined compliance environment. He explained that such a framework allows firms focused on institutional-grade digital assets to move forward more confidently. 
<figure class="wp-block-image size-full"><a href="https://benzinga.swoogo.com/digital-assets/6342807"><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/14000738/905735A6-57D3-4874-9AA1-75D037842DB3-1-15.gif" alt="" class="wp-image-646898" /></a></figure>
&#8220;Clear compliance frameworks open doors to institutional investment, which fosters stability and innovation,&#8221; Guren stated. According to him, this clarity could reduce uncertainty for traditional investors, encouraging capital flows into the European market and setting a strong foundation for future cross-border cooperation.
<h3 class="wp-block-heading">Impact on Regulated Investment Approaches</h3>
MiCA's structure also aligns with the needs of firms pursuing regulated investment strategies, such as Hunting Hill Global Capital, which is expanding into credit-focused strategies prioritizing transparency and investor trust. The additional compliance measures required by MiCA may come with initial costs. Still, Guren believes these costs are justified by the added security and structure they bring, making digital assets more attractive to a broad range of investors.
As the countdown to MiCA's implementation continues, Guren is expected to delve deeper into the potential of Europe's evolving crypto market at the <a href="https://benzinga.swoogo.com/digital-assets/6342807">Benzinga Future of Digital Assets </a>event, where industry leaders will discuss the regulation's possible effects on investment practices and market stability.
<hr class="wp-block-separator has-alpha-channel-opacity" />
As the digital asset market continues to mature, the convergence of regulatory shifts, M&amp;A activities, and adoption trends will define the future of this dynamic field.&nbsp;<a href="https://www.benzinga.com/digital-assets" target="_blank" rel="noreferrer noopener">Benzinga's Future of Digital Assets</a>&nbsp;event in New York City this November will provide industry leaders and investors with a platform to explore these developments further, offering insights into the evolving regulatory environment and the latest market dynamics.
Photo: DadBusiness via Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Events

Exclusives

Interview

MiCA Regulation Expected To Drive Institutional Interest In European Crypto Market

RBC Capital analyst Andrew Wong reiterates Mosaic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOS#NYSE">MOS</a>) with a Sector Perform and maintains $30 price target.

RBC Capital Reiterates Sector Perform on Mosaic, Maintains $30 Price Target

Roth MKM analyst Darren Aftahi maintains PSQ Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSQH#NYSE">PSQH</a>) with a Buy and lowers the price target from $5 to $3.5.

PSQH

Roth MKM Maintains Buy on PSQ Holdings, Lowers Price Target to $3.5

RBC Capital analyst Drew McReynolds maintains VerticalScope Holdings (TSX:<a class="ticker" href="https://www.benzinga.com/stock/FORA#TSX">FORA</a>) with a Outperform and raises the price target from C$15 to C$16.

TSX:FORA

RBC Capital Maintains Outperform on VerticalScope Holdings, Raises Price Target to C$16

Scotiabank analyst Meny Grauman maintains Sun Life Financial (TSX:<a class="ticker" href="https://www.benzinga.com/stock/SLF#TSX">SLF</a>) with a Sector Outperform and raises the price target from C$85 to C$96.

TSX:SLF

Scotiabank Maintains Sector Outperform on Sun Life Financial, Raises Price Target to C$96

Roth MKM analyst Richard Baldry reiterates OptimizeRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRX#NASDAQ">OPRX</a>) with a Buy and lowers the price target from $20 to $16.

OPRX

Roth MKM Reiterates Buy on OptimizeRx, Lowers Price Target to $16

Mastercard Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MA#NYSE">MA</a>) shares are trading higher on Thursday after the company unveiled on Wednesday its vision to transform online shopping by 2030, aiming to eliminate the need for physical card numbers, passwords, and one-time codes to <a href="https://www.benzinga.com/pressreleases/24/11/b41952965/mastercard-reinvents-checkout-with-password-and-number-free-payments">streamline the checkout experience.</a>
By 2030, Mastercard plans to eliminate manual card entry and static passwords, using tokenization and biometric authentication for secure, seamless online checkout.
Tokenization, introduced a decade ago to safeguard sensitive data, will be integrated with biometric authentication to ensure that every online transaction across Mastercard&#8217;s network is both tokenized and authenticated, enhancing both convenience and security.
This transformation is already underway in major markets and is expected to become widespread in the near future.
Notably, over 30% of Mastercard transactions globally are currently tokenized through Mastercard Digital Enablement Service (MDES), with markets like India approaching 100% tokenization for e-commerce.
Jorn Lambert, chief product officer at Mastercard, said, &#8220;Just like the transition from signing and swiping to tapping cards, we&#8217;re now moving from manual entry and passwords to seamless and secure payments in just a few clicks. With this shift we are protecting sensitive data through advanced encryption and tokenization technologies,&#8221;
&#8220;As payments continue to be embedded across a range of commerce experiences, we&#8217;re leading the way to a global economy that empowers everyone – providing consumers with greater control, convenience and peace-of-mind while unlocking new sales for merchants, and lowering fraud for issuers,&#8221; he added.
On Wednesday, Mastercard stated that it expects slower net revenue growth, projecting &#8220;low-double-digits&#8221; CAGR for 2025-2027, down <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41948028/mastercard-lowers-financial-forecast-signals-slower-eps-revenue-growth-ahead" target="_blank" rel="noreferrer noopener">from prior high-teens forecast</a>.
The company anticipates mid-teens EPS growth over the next three years, lowering expectations from earlier low-20s guidance.
Investors can gain exposure to the stock via&nbsp;iShares U.S. Financial Services ETF&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IYG#NYSE">IYG</a>) and&nbsp;BlackRock Long-Term U.S. Equity ETF&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BELT#NASDAQ">BELT</a>).
Price Action: MA shares were down 0.09% at $521.39 at last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/10/41659697/mastercard-q3-earnings-revenue-and-eps-beat-cross-border-transactions-growth-sees-european-consumer" target="_blank" rel="noreferrer noopener">Mastercard Q3 Earnings: Revenue And EPS Beat, Cross Border Transactions Growth, Sees European Consumer Confidence Improvement</a></li>
</ul>
Photo: Shutterstock

Equities

Large Cap

Tech

BELT

iShares Trust Dow Jones US Financial Services Index Fund

Mastercard's 2030 Vision: A Future Without Passwords, Card Numbers

RBC Capital analyst Chris Dendrinos reiterates Westport Fuel Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WPRT#NASDAQ">WPRT</a>) with a Sector Perform and maintains $8 price target.

WPRT

RBC Capital Reiterates Sector Perform on Westport Fuel Systems, Maintains $8 Price Target

Scotiabank analyst Himanshu Gupta maintains Slate Grocery (TSX:<a class="ticker" href="https://www.benzinga.com/stock/SGR#TSX">SGR</a>) with a Sector Perform and raises the price target from C$9 to C$10.

TSX:SGR

TSX:SGR/UN

Scotiabank Maintains Sector Perform on Slate Grocery, Raises Price Target to C$10

FirstEnergy Secures $50M U.S. Department Of Energy Grant For Smart Grid Enhancements, Aiming To Boost Reliability For Over 53,000 Customers In West Virginia And Maryland

Roth MKM analyst Richard Baldry reiterates Forian (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FORA#NASDAQ">FORA</a>) with a Buy and maintains $5 price target.

FORA

Roth MKM Reiterates Buy on Forian, Maintains $5 Price Target

Roth MKM analyst George Kelly reiterates Topgolf Callaway Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MODG#NYSE">MODG</a>) with a Buy and lowers the price target from $17 to $16.

MODG

Roth MKM Reiterates Buy on Topgolf Callaway Brands, Lowers Price Target to $16

WIIM

WYNN

Wynn Resorts shares are trading higher after Tilman Fertitta disclosed a 9.9% passive stake in the company.

Quince Therapeutics GAAP EPS of -$0.26

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Quince Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/qncx-stock-quote/">QNCX</a>) just reported results for the first quarter of 2024.<ul><li>Quince Therapeutics reported earnings per share of -26 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/qncx-stock-earnings-quince-therapeutics-for-q1-of-2024/">QNCX Stock Earnings: Quince Therapeutics Reported Results for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

QNCX Stock Earnings: Quince Therapeutics Reported Results for Q1 2024

Quince Therapeutics GAAP EPS of -$0.64

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Quince Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/qncx-stock-quote/">QNCX</a>) just reported results for the second quarter of 2024.<ul><li>Quince Therapeutics reported earnings per share of -19 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/qncx-stock-earnings-quince-therapeutics-for-q2-of-2024/">QNCX Stock Earnings: Quince Therapeutics Reported Results for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

QNCX Stock Earnings: Quince Therapeutics Reported Results for Q2 2024

Quince Therapeutics: High-Potential Turnaround With Phase 3 Asset EryDex

EF Hutton analyst Jason Kolbert initiated coverage of Quince Therapeutics (QNCX) with a Buy rating and $12 price target Quince is a biotechnology c...

Quince Therapeutics initiated with a Buy at EF Hutton

Rodman & Renshaw initiated coverage of Quince Therapeutics (QNCX) with a Buy rating and $11 price target Published first on TheFly – the ultimate s...

Quince Therapeutics initiated with a Buy at Rodman & Renshaw

Quince Therapeutics (QNCX) announced the poster presentation at the 53rd Child Neurology Society Annual Meeting of safety data from its prior Phase...

Quince Therapeutics presents safety data from ATTeST trial at CNS meeting

Quince Therapeutics (QNCX) "announced the presentation of two posters at the 2024 International Congress for Ataxia Research (ICAR) of data from it...

Quince Therapeutics presents data from prior Phase 3 ATTeST clinical trial

Quince Therapeutics GAAP EPS of -$0.13 beats by $0.02

QNCX

Press Releases

Quince Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results

Quince Therapeutics Receives U.S. FDA Fast Track Designation for EryDex System

Quince Therapeutics Announces First Patient Dosed in Phase 3 Clinical Trial of EryDex for the Treatment of Ataxia-Telangiectasia

Quince Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results

Quince Therapeutics Announces The Lancet Neurology Publication of Phase 3 ATTeST Clinical Trial Data Evaluating EryDex for the Treatment of Ataxia-Telangiectasia (A-T)

Comments

Quince Therapeutics

Quince Therapeutics (QNCX) Opciones

Quince Therapeutics (NASDAQ:QNCX) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL